The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life

Anitra C Carr, Margreet C M Vissers, John S Cook, Anitra C Carr, Margreet C M Vissers, John S Cook

Abstract

Cancer patients commonly experience a number of symptoms of disease progression and the side-effects of radiation therapy and adjuvant chemotherapy, which adversely impact on their quality of life (QOL). Fatigue is one of the most common and debilitating symptom reported by cancer patients and can affect QOL more than pain. Several recent studies have indicated that intravenous (IV) vitamin C alleviates a number of cancer- and chemotherapy-related symptoms, such as fatigue, insomnia, loss of appetite, nausea, and pain. Improvements in physical, role, cognitive, emotional, and social functioning, as well as an improvement in overall health, were also observed. In this mini review, we briefly cover the methods commonly used to assess health-related QOL in cancer patients, and describe the few recent studies examining the effects of IV vitamin C on cancer- and chemotherapy-related QOL. We discuss potential mechanisms that might explain an improvement in QOL and also considerations for future studies.

Keywords: cancer; chemotherapy; fatigue; quality of life; vitamin C.

References

    1. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One (2010) 5(7):e11414.10.1371/journal.pone.0011414
    1. Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP. Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol (2014) 10(1):22–37.10.1111/ajco.12173
    1. Parrow NL, Leshin JA, Levine M. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal (2013) 19(17):2141–56.10.1089/ars.2013.5372
    1. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 140(7):533–7.10.7326/0003-4819-140-7-200404060-00010
    1. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta (2012) 1826(2):443–57.10.1016/j.bbcan.2012.06.003
    1. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci (2007) 22(1):7–11.10.3346/jkms.2007.22.1.7
    1. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In vivo (2011) 25(6):983–90.
    1. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol (2013) 72(1):139–46.10.1007/s00280-013-2179-9
    1. Takahashi H, Mizuno H, Yanagisawa A. High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Med Universe (2012) 2(1):49–53.10.1016/j.pmu.2012.05.008
    1. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact (1974) 9(4):285–315.10.1016/0009-2797(74)90019-2
    1. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl (1982) 23:103–13.
    1. Bottomley A. The cancer patient and quality of life. Oncologist (2002) 7(2):120–5.10.1634/theoncologist.7-2-120
    1. Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol (2011) 22(10):2179–90.10.1093/annonc/mdq721
    1. Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics (2011) 29(8):673–85.10.2165/11588250-000000000-00000
    1. Glick HA, Shpall EJ, LeMaistre CF, McCarron TJ, Lu ZJ, Erder MH, et al. Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care (1998) 14(3):419–30.10.1017/S0266462300011405
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 85(5):365–76.10.1093/jnci/85.5.365
    1. Cocks K, King MT, Velikova G, de Castro G, Jr, Martyn St-James M, Fayers PM, et al. Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30. Eur J Cancer (2012) 48(11):1713–21.10.1016/j.ejca.2012.02.059
    1. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol (1997) 34(3 Suppl 2):4–12.
    1. Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage (2009) 37(1):107–28.10.1016/j.jpainsymman.2007.08.019
    1. Seyidova-Khoshknabi D, Davis MP, Walsh D. A systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care (2011) 28(2):119–29.10.1177/1049909110381590
    1. Stein KD, Martin SC, Hann DM, Jacobsen PB. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract (1998) 6(3):143–52.10.1046/j.1523-5394.1998.006003143.x
    1. Carr AC, Vissers MC, Cook J. Relief from cancer chemotherapy side effects with pharmacologic vitamin C. NZ Med J (2014) 127(1388):66–70.
    1. Carr AC, Vissers MCM, Cook J. Parenteral vitamin C for palliative care of terminal cancer patients. NZ Med J (2014) 127(1396):84–6.
    1. Miller M, Maguire R, Kearney N. Patterns of fatigue during a course of chemotherapy: results from a multi-centre study. Eur J Oncol Nurs (2007) 11(2):126–32.10.1016/j.ejon.2006.05.001
    1. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun (2013) 30(Suppl):S48–57.10.1016/j.bbi.2012.06.011
    1. Mercadante S, Fulfaro F. World health organization guidelines for cancer pain: a reappraisal. Ann Oncol (2005) 16(Suppl 4):iv132–5.10.1093/annonc/mdi922
    1. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med (2014) 6(222):222ra18.10.1126/scitranslmed.3007154
    1. Welsh JL, Wagner BA, van’t Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol (2013) 71(3):765–75.10.1007/s00280-013-2070-8
    1. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med (2005) 19(1):17–20.10.1191/0269216305pm970oa
    1. Mahdavi R, Faramarzi E, Seyedrezazadeh E, Mohammad-Zadeh M, Pourmoghaddam M. Evaluation of oxidative stress, antioxidant status and serum vitamin C levels in cancer patients. Biol Trace Elem Res (2009) 130(1):1–6.10.1007/s12011-008-8309-2
    1. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr (1999) 69(6):1086–107.
    1. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J (1999) 13(9):1007–24.
    1. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 49(11):1603–16.10.1016/j.freeradbiomed.2010.09.006
    1. Gilliam LA, St Clair DK. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal (2011) 15(9):2543–63.10.1089/ars.2011.3965
    1. Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 10:189.10.1186/1479-5876-10-189
    1. Mikirova N, Casciari J, Riordan N, Hunninghake R. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med (2013) 11(1):191.10.1186/1479-5876-11-191
    1. Rebouche CJ. Ascorbic acid and carnitine biosynthesis. Am J Clin Nutr (1991) 54(6 Suppl):1147S–52S.
    1. Schencking M, Vollbracht C, Weiss G, Lebert J, Biller A, Goyvaerts B, et al. Intravenous vitamin C in the treatment of shingles: results of a multicenter prospective cohort study. Med Sci Monit (2012) 18(4):CR215–24.10.12659/MSM.882621
    1. Chen JY, Chang CY, Feng PH, Chu CC, So EC, Hu ML. Plasma vitamin C is lower in postherpetic neuralgia patients and administration of vitamin C reduces spontaneous pain but not brush-evoked pain. Clin J Pain (2009) 25(7):562–9.10.1097/AJP.0b013e318193cf32
    1. Harrison FE, May JM. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med (2009) 46(6):719–30.10.1016/j.freeradbiomed.2008.12.018
    1. May JM, Qu ZC, Meredith ME. Mechanisms of ascorbic acid stimulation of norepinephrine synthesis in neuronal cells. Biochem Biophys Res Commun (2012) 426(1):148–52.10.1016/j.bbrc.2012.08.054
    1. Englard S, Seifter S. The biochemical functions of ascorbic acid. Annu Rev Nutr (1986) 6:365–406.10.1146/annurev.nu.06.070186.002053
    1. Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev (2010) (1):CD003974.10.1002/1451858.CD003974.pub3
    1. Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J, et al. Intravenous vitamin C and cancer: a systematic review. Integr Cancer Ther (2014) 13(4):280–300.10.1177/1534735414534463
    1. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol (2008) 19(11):1969–74.10.1093/annonc/mdn377
    1. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 7(1):e29794.10.1371/journal.pone.0029794
    1. Seely D, Stempak D, Baruchel S. A strategy for controlling potential interactions between natural health products and chemotherapy: a review in pediatric oncology. J Pediatr Hematol Oncol (2007) 29(1):32–47.10.1097/MPH.0b013e3180310521
    1. Dachs GU, Munn DG, Carr AC, Vissers MC, Robinson BA. Consumption of vitamin C is below recommended daily intake in many cancer patients and healthy volunteers in Christchurch. N Z Med J (2014) 127(1390):73–6.
    1. Lykkesfeldt J, Poulsen HE. Is vitamin C supplementation beneficial? Lessons learned from randomised controlled trials. Br J Nutr (2010) 103(9):1251–9.10.1017/S0007114509993229
    1. Ruddy KJ, Barton D, Loprinzi CL. Laying to rest psychostimulants for cancer-related fatigue? J Clin Oncol (2014) 32(18):1865–7.10.1200/JCO.2014.55.8353

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅